RBC Capital lowered the firm’s price target on Regenxbio (RGNX) to $17 from $21 and keeps an Outperform rating on the shares after its Q2 results. In DMD, the company’s pivotal trial that may lead to accelerated approval is ongoing, the analyst tells investors in a research note. RBC adds that it continues to like the setup given an undemanding valuation.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGNX: